ArticleJournal of clinical microbiology1999
Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.
Article in Journal of clinical microbiology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis.Intensive care medicine · 2005Pooled it
- Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era.Antibiotics (Basel, Switzerland) · 2022Article
- Article
- Synergistic and antagonistic effects of immunomodulatory drugs on the action of antifungals againstPeerJ · 2018Article
- Candidaemia observed at a university hospital in Milan (northern Italy) and review of published studies from 2010 to 2014.Mycopathologia · 2014Article
- Review
- Expression of mouse beta defensin 2 in escherichia coli and its broad-spectrum antimicrobial activity.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2011Article
- Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures.Therapeutics and clinical risk management · 2011Article
- Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007.BMC infectious diseases · 2010Article
- Article
- Substitution of methionine 63 or 83 in S100A9 and cysteine 42 in S100A8 abrogate the antifungal activities of S100A8/A9: potential role for oxidative regulation.FEMS immunology and medical microbiology · 2009Article
- Candida bloodstream infections in hemodialysis recipients.Medical mycology · 2009Article
- Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.Journal of clinical microbiology · 2008Article
- Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay.Antimicrobial agents and chemotherapy · 2008Article
- Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links.BMC infectious diseases · 2006Article
- Epidemiological trends in nosocomial candidemia in intensive care.BMC infectious diseases · 2006Article
- Biology of the pathogenic yeast Candida glabrata.Folia microbiologica · 2006Review
- Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.Antimicrobial agents and chemotherapy · 2005Article
- In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2004Article
- Inactivation of transcription factor gene ACE2 in the fungal pathogen Candida glabrata results in hypervirulence.Eukaryotic cell · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report describes both the trends in antifungal use and the epidemiology of nosocomial yeast infections at the University of Iowa Hospitals and Clinics between fiscal year (FY) 1987-1988 and FY 1993-1994. Data were gathered retrospectively from patients' medical records and from computerized databases maintained by the Pharmacy, the Program of Hospital Epidemiology, and the Medical Records Department. After fluconazole was introduced, use of ketoconazole decreased dramatically but adjusted use of amphotericin B decreased only moderately. However, the proportion of patients receiving antifungal therapy who were treated with amphotericin B declined markedly. In FY 1993-1994, 26 patients of the gastrointestinal surgery service received fluconazole. Among these patients, fluconazole use was prophylactic in 16 (61%), empiric in 3 (12%), and directed to a documented fungal infection in 7 (27%). Rates of nosocomial yeast infection in the adult bone marrow transplant unit increased from 6.77/1,000 patient days in FY 1987-1988 to 10.18 in FY 1989-1990 and then decreased to 0 in FY 1992-1993. Rates of yeast infections increased threefold in the medical and surgical intensive care units, reaching rates in FY 1993-1994 of 6.95 and 5.25/1,000 patient days, respectively. The rate of bloodstream infections increased from 0.044/1,000 patient days to 0.098, and the incidence of catheter-related urinary tract infections increased from 0.23/1,000 patient days to 0.68. Although the proportion of infections caused by yeast species other than Candida albicans did not increase consistently, C. glabrata became an important nosocomial pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.